AARD Stock Forecast & Price Target

Aardvark Therapeutics is supported by a compelling mechanistic thesis, as ARD-101’s gut-restricted TAS2R agonism is tied to CCK signaling and hypothalamic appetite regulation, with earlier phase IIa data showing reductions in hunger ratings and ghrelin levels. The company also benefits from a clear unmet need in hyperphagia associated with PWS and a regulatory backdrop that may allow flexibility, which strengthens the case for alignment with the FDA around the ongoing Phase 3 HERO study. While the studies have been small and variable, the cited $800M revenue opportunity in PWS, plus potential optionality from ARD-201 and combination obesity programs, supports a positive long-term view.

Aardvark Therapeutics is viewed negatively because ARD-101 remains under a formal FDA clinical hold, with no path to resume HERO or its OLE in their current form, and management has already said the completed 12-week data are insufficient for registration. The hold and EKG findings raise uncertainty around cardiac safety and suggest a narrower therapeutic window, while the company’s own outlook implies the timeline for ARD-101 in PWS could slip by 18 to 24 months even if the hold is lifted. As a clinical-stage biotech with no revenue, it also faces financing and dilution risk, while its DCF-based valuation of $168M enterprise value and $200M firm value remains highly dependent on uncertain approval probabilities and future trial success.